RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Caladrius Biosciences Stocks 2024

Caladrius Biosciences Stocks

5.18 M

Caladrius Biosciences Dividend yield

Ticker

CLBS

ISIN

US1280582032

WKN

A2APJW

In 2024, Caladrius Biosciences had 5.18 M outstanding stocks, a 0% change from the 5.18 M stocks in the previous year.

The Caladrius Biosciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e5.18
2025e5.18
2024e5.18
2023e5.18
20225.18
20213.69
20201.03
20190.69
20180.65
20170.6
20160.44
20154.85
20143.28
20132.05
20121.38
20110.89
20100.52
20090.13
20080.06
20070.03
20060.01
2005-
2004-
2003-

Caladrius Biosciences Aktienanalyse

What does Caladrius Biosciences do?

Caladrius Biosciences Inc was founded in 1980 as a pharmaceutical biotechnology company and is headquartered in Basking Ridge, New Jersey. The company focuses on developing cellular therapies for the treatment of serious diseases. Caladrius Biosciences aims to improve the lives of patients with unmet medical needs by developing novel and innovative therapies based on neuroscientific, immunological, and regenerative approaches. The business model of Caladrius Biosciences is based on researching and developing products that focus on the needs of patients. The goal is to concentrate on innovative and groundbreaking therapies that can treat diseases that have not been adequately treated before. The company has developed a portfolio of groundbreaking products based on stem cell, immune, and regenerative therapies. Caladrius Biosciences has three different business areas: - The first business area is its subsidiary PCT, LLC, which offers clinical manufacturing services in the field of clinical cell therapies. The subsidiary provides a scalable platform for the production of individual cell-based therapies. - The second business area is conducting clinical trials, including in the field of cardiovascular diseases. Caladrius Biosciences collaborates closely with clinics, doctors, and other professionals to demonstrate the potential of its own products through clinical studies. - The third area is the development of innovative therapies for diseases that previously could not be treated. The company is working on regenerative, immunological, and stem cell therapies. Caladrius has various products in development based on novel technologies, such as stem cell therapy. The company focuses on cardiovascular diseases, autoimmune diseases, and cancer. One of the flagship products of the company is CLBS201, which is a stem cell treatment for coronary heart disease. It is an autologous cell-based product derived from a patient's bone marrow and is used in combination with angioplasty, a minimally invasive surgical procedure to widen narrowed or blocked blood vessels. In summary, Caladrius Biosciences Inc is a leading biopharmaceutical company that focuses on developing innovative stem cell and immune therapies for the treatment of serious diseases. The company prioritizes the needs of patients and has established a unique position in the regenerative and cell-based therapy industry. Caladrius Biosciences pursues a long-term and sustainable growth model by relying on innovative technologies and clinical trials to continue developing groundbreaking products. In short, Caladrius Biosciences tirelessly works to improve the lives of people and cure diseases that were previously considered incurable. Caladrius Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Caladrius Biosciences's Shares Outstanding

Caladrius Biosciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Caladrius Biosciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Caladrius Biosciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Caladrius Biosciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Caladrius Biosciences Stock

How many stocks are there of Caladrius Biosciences?

The current number of stocks of Caladrius Biosciences is 5.18 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Caladrius Biosciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Caladrius Biosciences evolved in recent years?

The number of shares of Caladrius Biosciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Caladrius Biosciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Caladrius Biosciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Caladrius Biosciences pay?

Over the past 12 months, Caladrius Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Caladrius Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Caladrius Biosciences?

The current dividend yield of Caladrius Biosciences is .

When does Caladrius Biosciences pay dividends?

Caladrius Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Caladrius Biosciences?

Caladrius Biosciences paid dividends every year for the past 0 years.

What is the dividend of Caladrius Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Caladrius Biosciences located?

Caladrius Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Caladrius Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Caladrius Biosciences from 5/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/4/2024.

When did Caladrius Biosciences pay the last dividend?

The last dividend was paid out on 5/4/2024.

What was the dividend of Caladrius Biosciences in the year 2023?

In the year 2023, Caladrius Biosciences distributed 0 USD as dividends.

In which currency does Caladrius Biosciences pay out the dividend?

The dividends of Caladrius Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Caladrius Biosciences

Our stock analysis for Caladrius Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Caladrius Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.